-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Most meta-static castration-resistant prostate cancer (mCRPC) requires multi-line treatment, and each new treatment line has a shorter remission time
.
Such patients urgently need new targeted treatment options
.
Genotypic precision medicine (genotypic precision medicine) is widely known, which is based on the specific gene mutations of tumor cells to develop targeted treatment plans; while phenotypic precision medicine (phenotypic precision medicine) is a concept proposed in recent years, which refers to the Phenotypic biomarkers develop targeted treatment plans
.
Since more than 80% of prostate cancers highly express PSMA, precise radioligand therapy targeting this marker has high potential therapeutic value
.
On September 16, 2021, the New England Journal of Medicine (NEJM) officially published the Phase 3 clinical study of Sartor et al.
using 177Lu–PSMA-617 combined with standard therapy to treat mCRPC (this article was published online on June 23, 2021) The results showed that 177Lu-PSMA-617 combined with standard therapies significantly prolonged the imaging progression-free survival and overall survival of mCRPC
.
This research perfectly embodies the concept of phenotypic precision medicine
.
Here we invite the team of Professor Han Xingmin from the Nuclear Medicine Department of the First Affiliated Hospital of Zhengzhou University to comment on this study in depth
.
To read the full text translation, please visit the "NEJM Medical Frontiers" official website, APP or click on the picture of the WeChat applet
.
Han Xingmin*, Wang Ruihua, Xu Shasha Department of Nuclear Medicine, the First Affiliated Hospital of Zhengzhou University; Henan Provincial Key Laboratory of Molecular Imaging Medicine* Corresponding author Prostate cancer has become the tumor with the highest incidence in the urinary system, and the incidence of male malignant tumors in 2020 The rate and death rate are ranked 2nd and 5th respectively [1]
.
After locally advanced or metastatic prostate cancer undergoes androgen deprivation treatment, most patients progress to castration-resistant prostate cancer or mCRPC within about 1 year
.
mCRPC is the final stage of the malignant progression of prostate cancer and the main cause of death from prostate cancer; the patient’s prognosis is poor, with an overall survival period of less than two years
.
PSMA is a transmembrane glycoprotein that is specifically and highly expressed in prostate cancer cells.
Its expression level is 7 times and 17 times that of normal prostate cells and benign prostatic hyperplasia, and is found in high-grade tumors, metastatic or hormone-refractory Its expression gradually increases during diseases and androgen deprivation treatments.
These characteristics make it an effective target for the diagnosis and treatment of prostate cancer
.
In recent years, diagnosis and treatment based on PSMA have become the research hotspots of prostate cancer [2,3], such as antibody-drug conjugate therapy (MLN2704, PSMA-MMAE and MEDI3726), cellular immunotherapy (CAR-T, CAR/ NK-92 and PSMA BiTE)
.
Radionuclide-labeled PSMA small molecule inhibitors have also been widely used in prostate cancer diagnosis and radionuclide therapy [4,5], such as 99mTc-PSMA, a diagnostic SPECT imaging agent [6], PET imaging Agent 68Ga-PSMA, 18F-PSMA, etc.
[7], can realize the early diagnosis, staging, and efficacy evaluation of prostate cancer
.
In addition, PET-PSMA can detect occult prostate cancer lesions that were not detected by bone scan or CT
.
In terms of treatment, radionuclide-labeled PSMA ligands can target prostate cancer cells with positive PSMA expression by releasing α particles (Ac-225, Bi-213) or β particles (Lu-177, Y-90).
The surrounding microenvironment is used for in-vivo treatment
.
177Lu-PSMA-617 has a high affinity for targeted binding to PSMA, and the beta particles released by it directly irradiate prostate cancer cells and kill cancer cells, but have little effect on normal tissues [8-11]
.
NEJM officially published the results of the Phase 3 trial of 177Lu-PSMA-617 for mCRPC by Professor Sartor and his research team on September 16, 2021 [11]
.
The research team conducted an international, prospective, randomized, open-label, multi-center phase 3 of 831 mCRPC patients whose PET/CT scans confirmed PSMA positive in 84 centers around the world (52 in North America and 32 in Europe) The trial (VISION) evaluated the effectiveness and safety of 177Lu-PSMA-617 combined with the best standard treatment plan
.
The study enrolled 831 mCRPC patients who had previously received taxanes and Androgen Receptor Pathway Inhibition Therapy (ARDT) and had progressed on 68Ga-PSMA-11 PET/CT scans.
According to 2:1 The proportion of is randomly allocated to the experimental group and the control group
.
Patients in the experimental group received standard treatment combined with intravenous infusion of 177Lu-PSMA-617 at a dose of 7.
4 GBq (200 mCi), once every 6 weeks, for a total of 4 to 6 cycles
.
The control group received only the standard treatment specified by the investigator and physician
.
The main observational endpoints of this study are progression-free survival (PFS) and overall survival (OS) based on imaging
.
The median PFS of the 177Lu-PSMA-617 test group was 8.
7 months, and the control group was 3.
4 months (hazard ratio of progression or death, 0.
40; 99.
2% CI, 0.
29~0.
57; P<0.
001); median OS of the test group It was 15.
3 months and the control group was 11.
3 months (hazard ratio of death, 0.
62; 95% CI, 0.
52 to 0.
74; P<0.
001)
.
The key secondary endpoints are the patient's objective remission and disease control, and the time to the first symptomatic skeletal event or death
.
The median time from the test group to the first symptomatic skeletal event or death was 11.
5 months, while that of the control group was 6.
8 months; the test group experienced a decrease in PSA level, an improvement in quality of life (FACT-P score), and pain relief (BPI).
-SF score) is also better than the control group
.
The results of the study show that the PSMA-targeted radioligand 177Lu-PSMA-617 can prolong the OS of patients with mCRPC expressing PSMA and delay the progression of imaging.
Therefore, the combination of 177Lu-PSMA-617 radionuclide therapy in the standard treatment plan is effective
.
The study also observed the biological safety of 177Lu-PSMA-617
.
The median duration of patients exposed to 177Lu-PSMA-617 was 6.
9 months (0.
3~10.
2), and the median cumulative dose was 37.
5 GBq (7.
0~48.
3); the incidence of grade 3 or above adverse events during treatment, the experimental group Higher than the control group (52.
7% vs.
38.
0%)
.
The most common adverse events in the experimental group were fatigue, dry mouth, and nausea, and almost all were grade 1 or 2
.
The purpose of this study is to evaluate the gain and safety of 177Lu-PSMA-617 for standard treatment regimens for mCRPC patients, and it is not separately compared with other specific treatment methods
.
A multicenter, non-blinded, randomized phase 2 trial (TheraP) compared the efficacy of 177Lu-PSMA-617 with cabazitaxel in the treatment of mCRPC patients, with a PSA level of at least 50% lower than baseline as the primary endpoint
.
The results showed that the PSA remission rate of patients in the 177Lu-PSMA-617 group was higher than that of the cabazitaxel group, and the incidence of grade 3 to 4 adverse events was lower than that of the cabazitaxel group [12]
.
The results of the TheraP study and the VISION study are complementary, confirming that 177Lu-PSMA-617 is expected to have a better curative effect for patients who are about to receive cabazitaxel or who are not suitable for receiving taxon drugs
.
After the results of the study were reported at the 2021 meeting of the American Society of Clinical Oncology (ASCO), ASCO Chairman Professor Lori J.
Pierce commented: “This research is very important
.
177Lu-PSMA-617 can be delivered directly to prostate cancer cells, and patients The survival period has been significantly improved
.
If the drug can be approved by regulatory agencies, it will become a very important treatment option for mCRPC patients
.
"
We believe that the breakthrough data of this large-scale multi-center clinical trial will bring greater benefits to the treatment of prostate cancer, especially mCRPC in the near future
.
NEJM Quick Take introduces this article in the form of animation in 2 minutes
.
"NEJM Frontiers in Medicine" simultaneously updates the video summary of the current NEJM treatise with Chinese subtitles, allowing readers to quickly grasp the essence of the article
.
Radioligand Therapy Lutetium-177–PSMA-617 for Prostate Cancer Lutetium-177–PSMA-617 for Prostate Cancer September 16, 2021 Reader: Dr.
Stephen Morrissey, NEJM Executive Editor Reference 1.
Sung H, Ferlay J , Siegel RL, et al.
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin 2021;71:209-49.
2.
Wang F, Li Z, Feng X, Yang D, Lin M.
Advances in PSMA-targeted therapy for prostate cancer.
Prostate Cancer Prostatic Dis 2021 May 28 Doi:10.
1038/s41391-021 -00394-5 (Epub ahead of print).
3.
Sun M, Niaz MJ, Niaz MO , Tagawa ST.
Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapies for prostate cancer.
Curr Oncol Rep 2021;23:59.
4.
Cimadamore A, Cheng M, Santoni M, et al.
New prostate cancer targets for diagnosis, imaging, and therapy:Focus on prostate-specific membrane antigen.
Front Oncol 2018;8:653.
5.
Wester HJ, Schottelius M.
PSMA-targeted radiopharmaceuticals for imaging and therapy.
Semin Nucl Med 2019;49:302-12.
6.
Albalooshi B, Al Sharhan M, Bagheri F, et al.
Direct comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer.
Asia Ocean J Nucl Med Biol 2020;8:1-7.
7.
Oh SW, Cheon GJ.
Prostate-specific membrane antigen PET imaging in prostate cancer: Opportunities and challenges.
Korean J Radiol 2018;19:819-31.
8.
Kratochwil C, Bruchertseifer F, Rathke H, et al.
Targeted α-therapy of metastatic castration -resistant prostate cancer with 225Ac-PSMA-617: Dosimetry estimate and empiric dose finding.
J Nucl Med 2017;58:1624-31.
9.
Sathekge M, Knoesen O, Meckel M, Modiselle M, Vorster M, Marx S.
213Bi-PSMA -617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer.
Eur J Nucl Med Mol Imaging 2017;44:1099-100.
10.
Rathke H, Flechsig P, Mier W, et al.
Dosimetry estimate and initial clinical experience with (90)y-PSMA-617.
J Nucl Med 2019;60:806-11.
11.
Sartor O, de Bono J, Chi KN, et al.
Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer .
N Engl J Med 2021;385:1091-103.
12.
Hofman MS, Emmett L, Sandhu S, et al.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised , open-label, phase 2 trial.
Lancet 2021;397:797-804.
Author introduction Han Xingmin, chief physician, second-level professor, master tutorDosimetry estimate and initial clinical experience with (90)y-PSMA-617.
J Nucl Med 2019;60:806-11.
11.
Sartor O, de Bono J, Chi KN, et al.
Lutetium-177-PSMA-617 for metastatic castration -resistant prostate cancer.
N Engl J Med 2021;385:1091-103.
12.
Hofman MS, Emmett L, Sandhu S, et al.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP ): A randomised, open-label, phase 2 trial.
Lancet 2021;397:797-804.
Author introduction Han Xingmin, chief physician, second-level professor, master tutorDosimetry estimate and initial clinical experience with (90)y-PSMA-617.
J Nucl Med 2019;60:806-11.
11.
Sartor O, de Bono J, Chi KN, et al.
Lutetium-177-PSMA-617 for metastatic castration -resistant prostate cancer.
N Engl J Med 2021;385:1091-103.
12.
Hofman MS, Emmett L, Sandhu S, et al.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP ): A randomised, open-label, phase 2 trial.
Lancet 2021;397:797-804.
Author introduction Han Xingmin, chief physician, second-level professor, master tutorA randomised, open-label, phase 2 trial.
Lancet 2021;397:797-804.
Author introduction Han Xingmin, chief physician, second-level professor, master tutorA randomised, open-label, phase 2 trial.
Lancet 2021;397:797-804.
Author introduction Han Xingmin, chief physician, second-level professor, master tutor
.
Director of the Nuclear Medicine Department of the First Affiliated Hospital of Zhengzhou University
.
The current Vice President of the Nuclear Medicine Physician Branch of the Chinese Medical Doctor Association, the Deputy Secretary-General of the Nuclear Medicine Branch of the Chinese Medical Association, the Deputy Chairman of the Nuclear Medicine Equipment and Technology Professional Committee of the Chinese Medical Equipment Association, the executive director of the Nuclear Medicine Branch of the Chinese Nuclear Society, and the Henan Medical Association Director of Nuclear Medicine Branch, Director of Henan Provincial Nuclear Medicine Quality Control Center, Director of Henan Provincial Key Laboratory of Molecular Imaging Medicine, Standing Editor of Chinese Journal of Nuclear Medicine and Molecular Imaging, and Editorial Board of International Journal of Radiation Medicine and Nuclear Medicine
.
He specializes in the application and research of nuclear medicine in tumors and cardiovascular diseases.
He has published more than 100 professional articles and won 5 provincial and departmental scientific research achievements
.
Wang Ruihua, Doctor of Medicine, Associate Chief Physician, Associate Professor, Master Tutor
.
Deputy Director of the Nuclear Medicine Department of the First Affiliated Hospital of Zhengzhou University
.
He is currently a youth committee member of the Nuclear Medicine Branch of the Chinese Medical Association, a youth committee member of the Nuclear Medicine Physician Branch of the Chinese Medical Doctor Association, a member of the Information and Media Group of the Nuclear Medicine Branch of the Chinese Medical Association, a member and secretary of the Continuing Education Working Committee of the Nuclear Medicine Physician Branch of the Chinese Medical Doctor Association, Henan Member and Secretary of the Standing Committee of the Nuclear Medicine Branch of the Medical Association
.
Engaged in nuclear medicine professional medical treatment, teaching, and scientific research for 15 years, specializing in the application and research of nuclear medicine in tumor diagnosis and thyroid disease treatment
.
Successively presided over and completed 1 National Natural Science Foundation of China, and undertook 3 provincial and departmental scientific research projects
.
Published more than 20 scientific research papers, of which 3 were collected by SCI, and participated in the publication of 2 monographs
.
Xu Shasha, Ph.
D.
, chemist and assistant researcher in the Nuclear Medicine Department of the First Affiliated Hospital of Zhengzhou University
.
He has participated in 2 general projects of the National Natural Science Foundation of China, 1 key project supported by the Ministry of Science and Technology, 4 provincial and departmental scientific research projects, and undertook 2 provincial and departmental scientific research projects as the host
.
Published more than 10 scientific research papers, including 4 SCI papers as the first author
.
Copyright information This article was translated, written or commissioned by the "NEJM Frontiers of Medicine" jointly created by the Jiahui Medical Research and Education Group (J-Med) and the "New England Journal of Medicine" (NEJM)
.
The Chinese translation of the full text and the included diagrams are exclusively authorized by the NEJM Group
.
If you need to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
cn
.
Unauthorized translation is an infringement, and the copyright owner reserves the right to pursue legal liabilities
.
.
Such patients urgently need new targeted treatment options
.
Genotypic precision medicine (genotypic precision medicine) is widely known, which is based on the specific gene mutations of tumor cells to develop targeted treatment plans; while phenotypic precision medicine (phenotypic precision medicine) is a concept proposed in recent years, which refers to the Phenotypic biomarkers develop targeted treatment plans
.
Since more than 80% of prostate cancers highly express PSMA, precise radioligand therapy targeting this marker has high potential therapeutic value
.
On September 16, 2021, the New England Journal of Medicine (NEJM) officially published the Phase 3 clinical study of Sartor et al.
using 177Lu–PSMA-617 combined with standard therapy to treat mCRPC (this article was published online on June 23, 2021) The results showed that 177Lu-PSMA-617 combined with standard therapies significantly prolonged the imaging progression-free survival and overall survival of mCRPC
.
This research perfectly embodies the concept of phenotypic precision medicine
.
Here we invite the team of Professor Han Xingmin from the Nuclear Medicine Department of the First Affiliated Hospital of Zhengzhou University to comment on this study in depth
.
To read the full text translation, please visit the "NEJM Medical Frontiers" official website, APP or click on the picture of the WeChat applet
.
Han Xingmin*, Wang Ruihua, Xu Shasha Department of Nuclear Medicine, the First Affiliated Hospital of Zhengzhou University; Henan Provincial Key Laboratory of Molecular Imaging Medicine* Corresponding author Prostate cancer has become the tumor with the highest incidence in the urinary system, and the incidence of male malignant tumors in 2020 The rate and death rate are ranked 2nd and 5th respectively [1]
.
After locally advanced or metastatic prostate cancer undergoes androgen deprivation treatment, most patients progress to castration-resistant prostate cancer or mCRPC within about 1 year
.
mCRPC is the final stage of the malignant progression of prostate cancer and the main cause of death from prostate cancer; the patient’s prognosis is poor, with an overall survival period of less than two years
.
PSMA is a transmembrane glycoprotein that is specifically and highly expressed in prostate cancer cells.
Its expression level is 7 times and 17 times that of normal prostate cells and benign prostatic hyperplasia, and is found in high-grade tumors, metastatic or hormone-refractory Its expression gradually increases during diseases and androgen deprivation treatments.
These characteristics make it an effective target for the diagnosis and treatment of prostate cancer
.
In recent years, diagnosis and treatment based on PSMA have become the research hotspots of prostate cancer [2,3], such as antibody-drug conjugate therapy (MLN2704, PSMA-MMAE and MEDI3726), cellular immunotherapy (CAR-T, CAR/ NK-92 and PSMA BiTE)
.
Radionuclide-labeled PSMA small molecule inhibitors have also been widely used in prostate cancer diagnosis and radionuclide therapy [4,5], such as 99mTc-PSMA, a diagnostic SPECT imaging agent [6], PET imaging Agent 68Ga-PSMA, 18F-PSMA, etc.
[7], can realize the early diagnosis, staging, and efficacy evaluation of prostate cancer
.
In addition, PET-PSMA can detect occult prostate cancer lesions that were not detected by bone scan or CT
.
In terms of treatment, radionuclide-labeled PSMA ligands can target prostate cancer cells with positive PSMA expression by releasing α particles (Ac-225, Bi-213) or β particles (Lu-177, Y-90).
The surrounding microenvironment is used for in-vivo treatment
.
177Lu-PSMA-617 has a high affinity for targeted binding to PSMA, and the beta particles released by it directly irradiate prostate cancer cells and kill cancer cells, but have little effect on normal tissues [8-11]
.
NEJM officially published the results of the Phase 3 trial of 177Lu-PSMA-617 for mCRPC by Professor Sartor and his research team on September 16, 2021 [11]
.
The research team conducted an international, prospective, randomized, open-label, multi-center phase 3 of 831 mCRPC patients whose PET/CT scans confirmed PSMA positive in 84 centers around the world (52 in North America and 32 in Europe) The trial (VISION) evaluated the effectiveness and safety of 177Lu-PSMA-617 combined with the best standard treatment plan
.
The study enrolled 831 mCRPC patients who had previously received taxanes and Androgen Receptor Pathway Inhibition Therapy (ARDT) and had progressed on 68Ga-PSMA-11 PET/CT scans.
According to 2:1 The proportion of is randomly allocated to the experimental group and the control group
.
Patients in the experimental group received standard treatment combined with intravenous infusion of 177Lu-PSMA-617 at a dose of 7.
4 GBq (200 mCi), once every 6 weeks, for a total of 4 to 6 cycles
.
The control group received only the standard treatment specified by the investigator and physician
.
The main observational endpoints of this study are progression-free survival (PFS) and overall survival (OS) based on imaging
.
The median PFS of the 177Lu-PSMA-617 test group was 8.
7 months, and the control group was 3.
4 months (hazard ratio of progression or death, 0.
40; 99.
2% CI, 0.
29~0.
57; P<0.
001); median OS of the test group It was 15.
3 months and the control group was 11.
3 months (hazard ratio of death, 0.
62; 95% CI, 0.
52 to 0.
74; P<0.
001)
.
The key secondary endpoints are the patient's objective remission and disease control, and the time to the first symptomatic skeletal event or death
.
The median time from the test group to the first symptomatic skeletal event or death was 11.
5 months, while that of the control group was 6.
8 months; the test group experienced a decrease in PSA level, an improvement in quality of life (FACT-P score), and pain relief (BPI).
-SF score) is also better than the control group
.
The results of the study show that the PSMA-targeted radioligand 177Lu-PSMA-617 can prolong the OS of patients with mCRPC expressing PSMA and delay the progression of imaging.
Therefore, the combination of 177Lu-PSMA-617 radionuclide therapy in the standard treatment plan is effective
.
The study also observed the biological safety of 177Lu-PSMA-617
.
The median duration of patients exposed to 177Lu-PSMA-617 was 6.
9 months (0.
3~10.
2), and the median cumulative dose was 37.
5 GBq (7.
0~48.
3); the incidence of grade 3 or above adverse events during treatment, the experimental group Higher than the control group (52.
7% vs.
38.
0%)
.
The most common adverse events in the experimental group were fatigue, dry mouth, and nausea, and almost all were grade 1 or 2
.
The purpose of this study is to evaluate the gain and safety of 177Lu-PSMA-617 for standard treatment regimens for mCRPC patients, and it is not separately compared with other specific treatment methods
.
A multicenter, non-blinded, randomized phase 2 trial (TheraP) compared the efficacy of 177Lu-PSMA-617 with cabazitaxel in the treatment of mCRPC patients, with a PSA level of at least 50% lower than baseline as the primary endpoint
.
The results showed that the PSA remission rate of patients in the 177Lu-PSMA-617 group was higher than that of the cabazitaxel group, and the incidence of grade 3 to 4 adverse events was lower than that of the cabazitaxel group [12]
.
The results of the TheraP study and the VISION study are complementary, confirming that 177Lu-PSMA-617 is expected to have a better curative effect for patients who are about to receive cabazitaxel or who are not suitable for receiving taxon drugs
.
After the results of the study were reported at the 2021 meeting of the American Society of Clinical Oncology (ASCO), ASCO Chairman Professor Lori J.
Pierce commented: “This research is very important
.
177Lu-PSMA-617 can be delivered directly to prostate cancer cells, and patients The survival period has been significantly improved
.
If the drug can be approved by regulatory agencies, it will become a very important treatment option for mCRPC patients
.
"
We believe that the breakthrough data of this large-scale multi-center clinical trial will bring greater benefits to the treatment of prostate cancer, especially mCRPC in the near future
.
NEJM Quick Take introduces this article in the form of animation in 2 minutes
.
"NEJM Frontiers in Medicine" simultaneously updates the video summary of the current NEJM treatise with Chinese subtitles, allowing readers to quickly grasp the essence of the article
.
Radioligand Therapy Lutetium-177–PSMA-617 for Prostate Cancer Lutetium-177–PSMA-617 for Prostate Cancer September 16, 2021 Reader: Dr.
Stephen Morrissey, NEJM Executive Editor Reference 1.
Sung H, Ferlay J , Siegel RL, et al.
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin 2021;71:209-49.
2.
Wang F, Li Z, Feng X, Yang D, Lin M.
Advances in PSMA-targeted therapy for prostate cancer.
Prostate Cancer Prostatic Dis 2021 May 28 Doi:10.
1038/s41391-021 -00394-5 (Epub ahead of print).
3.
Sun M, Niaz MJ, Niaz MO , Tagawa ST.
Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapies for prostate cancer.
Curr Oncol Rep 2021;23:59.
4.
Cimadamore A, Cheng M, Santoni M, et al.
New prostate cancer targets for diagnosis, imaging, and therapy:Focus on prostate-specific membrane antigen.
Front Oncol 2018;8:653.
5.
Wester HJ, Schottelius M.
PSMA-targeted radiopharmaceuticals for imaging and therapy.
Semin Nucl Med 2019;49:302-12.
6.
Albalooshi B, Al Sharhan M, Bagheri F, et al.
Direct comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer.
Asia Ocean J Nucl Med Biol 2020;8:1-7.
7.
Oh SW, Cheon GJ.
Prostate-specific membrane antigen PET imaging in prostate cancer: Opportunities and challenges.
Korean J Radiol 2018;19:819-31.
8.
Kratochwil C, Bruchertseifer F, Rathke H, et al.
Targeted α-therapy of metastatic castration -resistant prostate cancer with 225Ac-PSMA-617: Dosimetry estimate and empiric dose finding.
J Nucl Med 2017;58:1624-31.
9.
Sathekge M, Knoesen O, Meckel M, Modiselle M, Vorster M, Marx S.
213Bi-PSMA -617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer.
Eur J Nucl Med Mol Imaging 2017;44:1099-100.
10.
Rathke H, Flechsig P, Mier W, et al.
Dosimetry estimate and initial clinical experience with (90)y-PSMA-617.
J Nucl Med 2019;60:806-11.
11.
Sartor O, de Bono J, Chi KN, et al.
Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer .
N Engl J Med 2021;385:1091-103.
12.
Hofman MS, Emmett L, Sandhu S, et al.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised , open-label, phase 2 trial.
Lancet 2021;397:797-804.
Author introduction Han Xingmin, chief physician, second-level professor, master tutorDosimetry estimate and initial clinical experience with (90)y-PSMA-617.
J Nucl Med 2019;60:806-11.
11.
Sartor O, de Bono J, Chi KN, et al.
Lutetium-177-PSMA-617 for metastatic castration -resistant prostate cancer.
N Engl J Med 2021;385:1091-103.
12.
Hofman MS, Emmett L, Sandhu S, et al.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP ): A randomised, open-label, phase 2 trial.
Lancet 2021;397:797-804.
Author introduction Han Xingmin, chief physician, second-level professor, master tutorDosimetry estimate and initial clinical experience with (90)y-PSMA-617.
J Nucl Med 2019;60:806-11.
11.
Sartor O, de Bono J, Chi KN, et al.
Lutetium-177-PSMA-617 for metastatic castration -resistant prostate cancer.
N Engl J Med 2021;385:1091-103.
12.
Hofman MS, Emmett L, Sandhu S, et al.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP ): A randomised, open-label, phase 2 trial.
Lancet 2021;397:797-804.
Author introduction Han Xingmin, chief physician, second-level professor, master tutorA randomised, open-label, phase 2 trial.
Lancet 2021;397:797-804.
Author introduction Han Xingmin, chief physician, second-level professor, master tutorA randomised, open-label, phase 2 trial.
Lancet 2021;397:797-804.
Author introduction Han Xingmin, chief physician, second-level professor, master tutor
.
Director of the Nuclear Medicine Department of the First Affiliated Hospital of Zhengzhou University
.
The current Vice President of the Nuclear Medicine Physician Branch of the Chinese Medical Doctor Association, the Deputy Secretary-General of the Nuclear Medicine Branch of the Chinese Medical Association, the Deputy Chairman of the Nuclear Medicine Equipment and Technology Professional Committee of the Chinese Medical Equipment Association, the executive director of the Nuclear Medicine Branch of the Chinese Nuclear Society, and the Henan Medical Association Director of Nuclear Medicine Branch, Director of Henan Provincial Nuclear Medicine Quality Control Center, Director of Henan Provincial Key Laboratory of Molecular Imaging Medicine, Standing Editor of Chinese Journal of Nuclear Medicine and Molecular Imaging, and Editorial Board of International Journal of Radiation Medicine and Nuclear Medicine
.
He specializes in the application and research of nuclear medicine in tumors and cardiovascular diseases.
He has published more than 100 professional articles and won 5 provincial and departmental scientific research achievements
.
Wang Ruihua, Doctor of Medicine, Associate Chief Physician, Associate Professor, Master Tutor
.
Deputy Director of the Nuclear Medicine Department of the First Affiliated Hospital of Zhengzhou University
.
He is currently a youth committee member of the Nuclear Medicine Branch of the Chinese Medical Association, a youth committee member of the Nuclear Medicine Physician Branch of the Chinese Medical Doctor Association, a member of the Information and Media Group of the Nuclear Medicine Branch of the Chinese Medical Association, a member and secretary of the Continuing Education Working Committee of the Nuclear Medicine Physician Branch of the Chinese Medical Doctor Association, Henan Member and Secretary of the Standing Committee of the Nuclear Medicine Branch of the Medical Association
.
Engaged in nuclear medicine professional medical treatment, teaching, and scientific research for 15 years, specializing in the application and research of nuclear medicine in tumor diagnosis and thyroid disease treatment
.
Successively presided over and completed 1 National Natural Science Foundation of China, and undertook 3 provincial and departmental scientific research projects
.
Published more than 20 scientific research papers, of which 3 were collected by SCI, and participated in the publication of 2 monographs
.
Xu Shasha, Ph.
D.
, chemist and assistant researcher in the Nuclear Medicine Department of the First Affiliated Hospital of Zhengzhou University
.
He has participated in 2 general projects of the National Natural Science Foundation of China, 1 key project supported by the Ministry of Science and Technology, 4 provincial and departmental scientific research projects, and undertook 2 provincial and departmental scientific research projects as the host
.
Published more than 10 scientific research papers, including 4 SCI papers as the first author
.
Copyright information This article was translated, written or commissioned by the "NEJM Frontiers of Medicine" jointly created by the Jiahui Medical Research and Education Group (J-Med) and the "New England Journal of Medicine" (NEJM)
.
The Chinese translation of the full text and the included diagrams are exclusively authorized by the NEJM Group
.
If you need to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
cn
.
Unauthorized translation is an infringement, and the copyright owner reserves the right to pursue legal liabilities
.
